The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.
The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback